Developer docs
API playgroundTry for free, no card

Search company profiles

Olema Oncology

Full company profile

uuid00006yc

Namestring
Olema Oncology
Legal namestring
Olema Pharmaceuticals, Inc.
Websiteurl
olema.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Olema Oncology (Olema Pharmaceuticals, Inc., NASDAQ: OLMA) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. The company develops targeted small-molecule therapeutics for estrogen receptor-positive (ER+) breast cancer and other solid tumors, with its lead asset palazestrant (OP-1250) currently in two pivotal Phase 3 trials (OPERA-01 as monotherapy and OPERA-02 in combination with ribociclib) for ER+/HER2- metastatic breast cancer, and a second asset, OP-3136, a KAT6 inhibitor in Phase 1 development for breast, prostate, and lung cancers.

Palazestrant is a first-in-class complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that fully blocks both AF1 and AF2 transcriptional activation domains through complete recruitment of the NCoR1 corepressor protein, yielding durable inhibition of ER-driven transcription regardless of ESR1 mutation status. OP-3136 is an orally available small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in multiple tumor types, and has shown synergistic anti-tumor activity when combined with palazestrant. The company has secured clinical collaborations with Novartis (ribociclib supply for OPERA-02), Pfizer (palbociclib combination studies), and Bayer (darolutamide combination for OP-3136).

Olema is pre-revenue and pre-commercial, generating no product revenue today and reporting a net loss of $162.5 million in 2025 against a cash position of $505.4 million (runway into mid-2028). The revenue model anticipates US product sales upon a planned 2027 commercial launch of palazestrant, with a global commercial partner to be sought for ex-US markets. Approximately 91.78% institutional ownership reflects a public-equity-financed capital structure, with cumulative capital raises of roughly $648.5 million between September 2023 and November 2025, including a $218.5 million public offering in November 2025. The company employs 101-250 staff, with a recently expanded commercial strategy function preparing for launch.

Short descriptiontext

Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for ER+/HER2- metastatic breast cancer, with lead asset palazestrant (OP-1250) in two pivotal Phase 3 trials and OP-3136 (KAT6 inhibitor) in Phase 1.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, breast cancer therapeutics, estrogen receptor antagonists, clinical-stage biopharmaceuticals, epigenetic cancer therapy
Industry3 codes
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Drug Development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue (Future)
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Expected to generate product revenue from commercialization of palazestrant, anticipated to launch in 2027. No product revenue currently as all candidates are in clinical development.

za.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Olema Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Its second candidate, OP-3136, is a selective KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. Both are investigational small molecule therapeutics intended for regulatory approval and commercial sale upon completion of clinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 3 OPERA-01 trial readout expected in fall 2026
+3 more records
Product overview1 text field

Olema Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer. The company's product portfolio consists of two investigational drug candidates: palazestrant (OP-1250), the lead product, is a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in Phase 3 clinical trials for ER+/HER2- metastatic breast cancer; and OP-3136, an earlier-stage KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. These two candidates represent the core offerings advancing through the company's clinical pipeline.

Product and service2 records
1Palazestrant (OP-1250)
CategoryOncology drug candidate - endocrine therapy
Description

A novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that blocks both transcriptional activation function domains AF1 and AF2 of the estrogen receptor, resulting in complete inhibition of ER-driven transcription regardless of ESR1 mutation status. Being evaluated as a single agent in the pivotal Phase 3 OPERA-01 trial and in combination with ribociclib in the pivotal Phase 3 OPERA-02 trial for ER+/HER2- metastatic breast cancer patients.

2OP-3136
CategoryOncology drug candidate - epigenetic therapy
Description

A novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in breast and other cancers. Shows evidence of anti-tumor activity across multiple solid tumor types including ER+/HER2- advanced breast cancer, metastatic castration-resistant prostate cancer, and metastatic non-small cell lung cancer. Currently in Phase 1 clinical trial.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Clinical trial collaboration and supply agreement to evaluate OP-3136 in combination with NUBEQA (darolutamide) in prostate cancer and other solid tumors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-02
Description

Clinical trial collaboration and supply agreement where Novartis supplies ribociclib (Kisqali) for the Phase 3 OPERA-02 trial evaluating palazestrant in combination with ribociclib for first-line treatment of ER+, HER2- advanced breast cancer. Trial initiation expected mid-2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration for palazestrant in combination with palbociclib (Ibrance) in Phase 1b/2 studies for ER+, HER2- breast cancer treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Italian pharma company that, with Radius Health, developed and commercializes elacestrant (Orserdu), the first FDA-approved oral SERD for ER+/HER2- metastatic breast cancer. Direct competitor in the same mechanism class and indication Olema is targeting with palazestrant.

TypeDirect peer
Description

Swiss pharma giant developing giredestrant, an oral SERD in Phase 3 development (persevERA trial) for ER+/HER2- metastatic breast cancer. Direct competitor with overlapping mechanism of action; Roche's failed persevERA trial recently caused a 25.8% decline in Olema's stock price.

TypeDirect peer
Description

Global pharma developing camizestrant, a next-generation oral SERD in late-stage SERENA trials for ER+/HER2- breast cancer. Direct competitor in the oral endocrine therapy space with deep oncology commercial infrastructure that could pressure palazestrant's market entry.

TypeDirect peer
Description

Clinical-stage biotech developing vepdegestrant (ARV-471), a PROTAC estrogen receptor degrader in Phase 3 development for ER+/HER2- breast cancer, partnered with Pfizer. Directly comparable as a late-stage ER-targeting oral therapy in the same indication.

TypeEmerging player
Description

Clinical-stage oncology company developing ZN-c5, an oral SERD for ER+/HER2- breast cancer. Smaller emerging competitor with a similar mechanism of action and indication focus, providing a useful benchmark for clinical-stage SERD valuations.

TypeEmerging player
Description

Private oncology company developing lasofoxifene, an oral selective estrogen receptor modulator for ESR1-mutated ER+ metastatic breast cancer. Comparable as a niche oral endocrine therapy targeting similar biomarker-defined patient populations as palazestrant.

TypeBroad incumbent
Description

Major pharma partner of Olema (supplying palbociclib for combination studies) and a competitor through its Arvinas partnership for vepdegestrant. Provides a useful comparison as a dominant oncology incumbent with endocrine therapy franchise (Ibrance) and competing ER-degrader development program.

TypeBroad incumbent
Description

Major pharma partner of Olema, supplying ribociclib (Kisqali) for the OPERA-02 combination Phase 3 trial and participating in the $250M private placement. Provides a relevant incumbent benchmark with established CDK4/6 franchise and global oncology commercial reach.

TypeDirect peer
Description

Biotech that originally developed elacestrant (Orserdu) before licensing to Menarini. Direct peer in oral SERD development for ER+/HER2- breast cancer and a useful precedent for clinical-to-commercial transitions in this space.

10H3 Biomedicine / Eisai
TypeEmerging player
Description

Eisai subsidiary developing H3B-6545, an oral selective estrogen receptor covalent antagonist (SERCA) for ER+ breast cancer. Comparable as a niche oral endocrine therapy developer targeting the same patient population with a differentiated covalent-binding mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Olema Oncology

Oncology Drug Developmentolema.com

Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for ER+/HER2- metastatic breast cancer, with lead asset palazestrant (OP-1250) in two pivotal Phase 3 trials and OP-3136 (KAT6 inhibitor) in Phase 1.

What Olema Oncology does

Olema Oncology (Olema Pharmaceuticals, Inc., NASDAQ: OLMA) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. The company develops targeted small-molecule therapeutics for estrogen receptor-positive (ER+) breast cancer and other solid tumors, with its lead asset palazestrant (OP-1250) currently in two pivotal Phase 3 trials (OPERA-01 as monotherapy and OPERA-02 in combination with ribociclib) for ER+/HER2- metastatic breast cancer, and a second asset, OP-3136, a KAT6 inhibitor in Phase 1 development for breast, prostate, and lung cancers.

Palazestrant is a first-in-class complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that fully blocks both AF1 and AF2 transcriptional activation domains through complete recruitment of the NCoR1 corepressor protein, yielding durable inhibition of ER-driven transcription regardless of ESR1 mutation status. OP-3136 is an orally available small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in multiple tumor types, and has shown synergistic anti-tumor activity when combined with palazestrant. The company has secured clinical collaborations with Novartis (ribociclib supply for OPERA-02), Pfizer (palbociclib combination studies), and Bayer (darolutamide combination for OP-3136).

Olema is pre-revenue and pre-commercial, generating no product revenue today and reporting a net loss of $162.5 million in 2025 against a cash position of $505.4 million (runway into mid-2028). The revenue model anticipates US product sales upon a planned 2027 commercial launch of palazestrant, with a global commercial partner to be sought for ex-US markets. Approximately 91.78% institutional ownership reflects a public-equity-financed capital structure, with cumulative capital raises of roughly $648.5 million between September 2023 and November 2025, including a $218.5 million public offering in November 2025. The company employs 101-250 staff, with a recently expanded commercial strategy function preparing for launch.

Olema Oncology firmographics

Firmographics
Name
Olema Oncology
Legal name
Olema Pharmaceuticals, Inc.
Website
https://olema.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for ER+/HER2- metastatic breast cancer, with lead asset palazestrant (OP-1250) in two pivotal Phase 3 trials and OP-3136 (KAT6 inhibitor) in Phase 1.
Ownership category
akta.pro rank

Olema Oncology industry classification

Industry
Product category
Oncology Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAJ
Breast Oncology
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology drug development
  • Breast cancer therapeutics
  • Estrogen receptor antagonists
  • Clinical-stage biopharmaceuticals
  • Epigenetic cancer therapy

Where Olema Oncology is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Olema Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Product Revenue (Future): Pre-revenue clinical-stage biopharmaceutical company. Expected to generate product revenue from commercialization of palazestrant, anticipated to launch in 2027. No product revenue currently as all candidates are in clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Olema Oncology product offering

Product offering

Core offering

Olema Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Its second candidate, OP-3136, is a selective KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. Both are investigational small molecule therapeutics intended for regulatory approval and commercial sale upon completion of clinical development.

Product overview

Olema Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer. The company's product portfolio consists of two investigational drug candidates: palazestrant (OP-1250), the lead product, is a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in Phase 3 clinical trials for ER+/HER2- metastatic breast cancer; and OP-3136, an earlier-stage KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. These two candidates represent the core offerings advancing through the company's clinical pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Palazestrant (OP-1250) A novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that blocks both transcriptional activation function domains AF1 and AF2 of the estrogen receptor, resulting in complete inhibition of ER-driven transcription regardless of ESR1 mutation status. Being evaluated as a single agent in the pivotal Phase 3 OPERA-01 trial and in combination with ribociclib in the pivotal Phase 3 OPERA-02 trial for ER+/HER2- metastatic breast cancer patients.
  • OP-3136 A novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in breast and other cancers. Shows evidence of anti-tumor activity across multiple solid tumor types including ER+/HER2- advanced breast cancer, metastatic castration-resistant prostate cancer, and metastatic non-small cell lung cancer. Currently in Phase 1 clinical trial.

Quantifiable outcome

  • Phase 3 OPERA-01 trial readout expected in fall 2026
  • +3 more outcomes

Companies that use Olema Oncology

Customer profile

Segments2 records

Ideal customer profiles2 records

Olema Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Olema Oncology partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • BayercoreStrategic or Co-development Partner · 26 May 2026Clinical trial collaboration and supply agreement to evaluate OP-3136 in combination with NUBEQA (darolutamide) in prostate cancer and other solid tumors.
  • NovartiscoreStrategic or Co-development Partner · 2 December 2024Clinical trial collaboration and supply agreement where Novartis supplies ribociclib (Kisqali) for the Phase 3 OPERA-02 trial evaluating palazestrant in combination with ribociclib for first-line treatment of ER+, HER2- advanced breast cancer. Trial initiation expected mid-2025.
  • PfizercoreStrategic or Co-development PartnerClinical collaboration for palazestrant in combination with palbociclib (Ibrance) in Phase 1b/2 studies for ER+, HER2- breast cancer treatment.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Olema Oncology competitors and assessment

Company assessment

Direct peers

  • Menarini Group: Italian pharma company that, with Radius Health, developed and commercializes elacestrant (Orserdu), the first FDA-approved oral SERD for ER+/HER2- metastatic breast cancer. Direct competitor in the same mechanism class and indication Olema is targeting with palazestrant.
  • Roche: Swiss pharma giant developing giredestrant, an oral SERD in Phase 3 development (persevERA trial) for ER+/HER2- metastatic breast cancer. Direct competitor with overlapping mechanism of action; Roche's failed persevERA trial recently caused a 25.8% decline in Olema's stock price.
  • AstraZeneca: Global pharma developing camizestrant, a next-generation oral SERD in late-stage SERENA trials for ER+/HER2- breast cancer. Direct competitor in the oral endocrine therapy space with deep oncology commercial infrastructure that could pressure palazestrant's market entry.
  • Arvinas: Clinical-stage biotech developing vepdegestrant (ARV-471), a PROTAC estrogen receptor degrader in Phase 3 development for ER+/HER2- breast cancer, partnered with Pfizer. Directly comparable as a late-stage ER-targeting oral therapy in the same indication.
  • Radius Health: Biotech that originally developed elacestrant (Orserdu) before licensing to Menarini. Direct peer in oral SERD development for ER+/HER2- breast cancer and a useful precedent for clinical-to-commercial transitions in this space.

Emerging players

  • Zentalis Pharmaceuticals: Clinical-stage oncology company developing ZN-c5, an oral SERD for ER+/HER2- breast cancer. Smaller emerging competitor with a similar mechanism of action and indication focus, providing a useful benchmark for clinical-stage SERD valuations.
  • Sermonix Pharmaceuticals: Private oncology company developing lasofoxifene, an oral selective estrogen receptor modulator for ESR1-mutated ER+ metastatic breast cancer. Comparable as a niche oral endocrine therapy targeting similar biomarker-defined patient populations as palazestrant.
  • H3 Biomedicine / Eisai: Eisai subsidiary developing H3B-6545, an oral selective estrogen receptor covalent antagonist (SERCA) for ER+ breast cancer. Comparable as a niche oral endocrine therapy developer targeting the same patient population with a differentiated covalent-binding mechanism.

Broad incumbents

  • Pfizer: Major pharma partner of Olema (supplying palbociclib for combination studies) and a competitor through its Arvinas partnership for vepdegestrant. Provides a useful comparison as a dominant oncology incumbent with endocrine therapy franchise (Ibrance) and competing ER-degrader development program.
  • Novartis: Major pharma partner of Olema, supplying ribociclib (Kisqali) for the OPERA-02 combination Phase 3 trial and participating in the $250M private placement. Provides a relevant incumbent benchmark with established CDK4/6 franchise and global oncology commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Olema Oncology social profiles

Digital presence

Olema Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Olema Oncology leadership team

Management profile

Number of profiles

Profiles16 records

Olema Oncology funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Olema Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olema Oncology

What does Olema Oncology do?

Olema Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Its second candidate, OP-3136, is a selective KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. Both are investigational small molecule therapeutics intended for regulatory approval and commercial sale upon completion of clinical development.

Is Olema Oncology a public or private company?

Olema Oncology is a public company. It is classified as public and is currently operating.

When was Olema Oncology founded?

Olema Oncology was founded in 2006. It employs 101 to 250 people.

Where is Olema Oncology based?

Olema Oncology is headquartered in San Francisco, United States, in the North America region.

How does Olema Oncology make money?

One revenue line is on record: product Revenue (Future).

Who are Olema Oncology's main competitors?

Direct peers on record are Menarini Group, Roche, AstraZeneca, Arvinas and Radius Health. Emerging players are Zentalis Pharmaceuticals, Sermonix Pharmaceuticals and H3 Biomedicine / Eisai. Broad incumbents are Pfizer and Novartis.

Does Olema Oncology have an API?

No public API is recorded for Olema Oncology.

What industry is Olema Oncology in?

Olema Oncology's product category is Oncology Drug Development. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comOlema Oncology at Jefferies Global Healthcare Conference: key trial tests aheadOlema Oncology presented its palazestrant strategy at Jefferies' healthcare conference, with OPERA-01 Phase III readout expected in Q1 2027. Phase II showed 7.3 months median PFS in ESR1 mutant and 5.5 months in wild-type patients. The company targets a $2 billion ESR1 mutant market and a $10 billion first-line combination trial.Seeking AlphaOlema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 TranscriptOlema Pharmaceuticals CEO Sean Bohen discussed the Phase III OPERA-01 study for palazestrant in second-line metastatic breast cancer at the UBS Global Biopharma Conference. The company expects Phase III data in early 2027, with the study targeting a $1 billion indication.Business & FinancialOlema Oncology Announces Corporate Name ChangeOlema Oncology announced a corporate name change, with no stockholder action required under Delaware law. The company's stock will continue trading on Nasdaq under ticker OLMA, and prior stock certificates remain valid. The company is developing palazestrant and OP-3136 for breast cancer.Stock TitanOlema Oncology changes name from Olema PharmaceuticalsOlema Oncology, Inc. changed its corporate name from Olema Pharmaceuticals, Inc. effective November 12, 2026, with no stockholder action required. The company's stock continues trading under the ticker OLMA on Nasdaq. Its lead product candidate, palazestrant, is in two Phase 3 trials, and it is developing OP-3136 in a Phase 1 study.GlobeNewswireOlema Oncology Announces Corporate Name ChangeOlema Oncology, Inc. changed its corporate name from Olema Pharmaceuticals, Inc. effective today, with no stockholder action required. The company's stock continues trading under the ticker OLMA on Nasdaq. Its lead product candidate, palazestrant, is in two Phase 3 trials, and it is developing OP-3136 in a Phase 1 study.MarketScreenerOlema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Olema Pharmaceuticals reported a Q3 net loss of $73.6 million, up from $42.2 million a year earlier, and a nine-month net loss of $189.9 million, up from $116.4 million. Basic and diluted loss per share from continuing operations were $0.73 and $1.89, respectively, compared to $0.49 and $1.36 a year ago.ChartmillOlema Pharmaceuticals (NASDAQ:OLMA) Posts Wider Q3 Loss as Phase 3 Trial Spend ClimbsOlema Pharmaceuticals reported a Q3 net loss of $73.6 million, wider than the $42.2 million prior year and a consensus estimate, with zero revenue. The loss stemmed from increased Phase 3 trial enrollment and higher personnel costs. The company has about $413.8 million in cash, funding roughly five to six quarters at current burn.The future of tradingOlema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings SummaryOlema Pharmaceuticals reported a quarterly adjusted loss of 73 cents per share for the quarter ended September 30, lower than the prior year's -49 cents. Revenue was zero, and the company's quarterly loss was $73.6 million. Analysts had expected a loss of 62 cents per share.American Banking and Market NewsCandriam S.C.A. Purchases 433,334 Shares of Olema Pharmaceuticals, Inc. $OLMACandriam S.C.A. bought 433,334 Olema Pharmaceuticals shares in Q3, raising its stake to 1.35% worth $10.27 million. The company reported a loss of $0.61 per share, missing estimates, and analysts give it a Moderate Buy rating with a $40.60 price target.YahooOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer SymposiumOlema Oncology will present clinical data from OP-3136 and palazestrant combination studies at the 2026 San Antonio Breast Cancer Symposium. The posters cover OP-3136 with fulvestrant, palazestrant with everolimus, and palazestrant with atirmociclib. The company also highlighted its pipeline, including palazestrant's Phase 3 trials.